OINDPnews


H&T Presspart banner

News

Tiotropium plus olodaterol improve lung function in Phase 2 study

According to Boehringer Ingelheim, a combination of tiotropium and olodaterol delivered using the Respimat soft mist inhaler significantly improved 24-hour FEV1 in COPD patients compared to olodaterol monotherapy at all doses tested. The 4-week double-blind study with 232 COPD patients testing doses of tiotropium of 1.25, 2.5, and 5 μg with either 5 μg or 10 μg of … [Read more...] about Tiotropium plus olodaterol improve lung function in Phase 2 study

Aradigm gets new method of treatment patent for nicotine inhaler

The United States Patent and Trademark Office has issued a method of treatment patent to Aradigm for its inhaled nicotine formulations. US Patent No. 8,256,433, for Systems and Methods for Effecting Cessation of Tobacco Use, provide exclusivity for the systems until January 7, 2024. Aradigm President and CEO Igor Gonda commented, “Tobacco smoking remains an … [Read more...] about Aradigm gets new method of treatment patent for nicotine inhaler

Rigel initiates Phase 2 study of inhaled SYK inhibitor for asthma

Rigel Pharmaceuticals says that it has begun a Phase 2 clinical study of its R343 nhaled SYK inhibitor that is being evaluated as a potential treatment for allergic asthma. The 8-week study, called SITAR (SYK Inhibition for Treatment of Asthma with R343), will compare two doses R343 and placebo in approximately 270 adult asthma patients and is expected to be completed … [Read more...] about Rigel initiates Phase 2 study of inhaled SYK inhibitor for asthma

Almirall opens Canadian affiliate, presents positive Phase 3 results for Eklira Genuair

Almirall has opened a new affiliate in Toronto, Canada. Having a presence in Canada will help the company roll out its recently approved aclidinium DPI for COPD, among other drugs, Almirall says. The company will co-market aclidinium as Tudorza Pressair with Forest Laboratories. In Europe, aclidinium bromide inhalers are being marketed as the Eklira Genuair and … [Read more...] about Almirall opens Canadian affiliate, presents positive Phase 3 results for Eklira Genuair

Study finds that inhaled budesonide for children reduces adult height

A study by the Childhood Asthma Management Program (CAMP) Research Group published online in the New England Journal of Medicine on September 3 finds that children who received 400 μg of inhaled budesonide daily for 4-6 years had a mean adult height 1.2 cm less than children who received placebo. The researchers obtained height measurements from 943 participants out … [Read more...] about Study finds that inhaled budesonide for children reduces adult height

Australian court issues injunction against Apotex in Nasonex case

The Federal Court of Australia has granted an injunction against Apotex, banning it from selling generic mometasone furoate nasal sprays in the country pending the outcome of a patent infringement lawsuit by Merck Sharpe & Dohme Australia. Apotex, which claims that MSD's patent is invalid, had already begun marketing the nasal sprays and intended to begin shipping … [Read more...] about Australian court issues injunction against Apotex in Nasonex case

FDA questions for Novartis about Tobi Podhaler prior to advisory committee meeting

The FDA briefing materials for the September 5, 2012 meeting of the Anti-Infective Drugs Advisory Committee, which will consider the use of Novartis's Tobi tobramycin inhalation powder (TIP) for the treatment of P. aeruginosa infections in cystic fibrosis patients, question both the efficacy and safety of the product, especially when compared to TOBI tobramycin … [Read more...] about FDA questions for Novartis about Tobi Podhaler prior to advisory committee meeting